Biotechnology

Corvus Pharma

Corvus Pharma released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1521 (forecast USD -0.146)

Corvus Pharma to Release FY2026 Q1 Earnings on May 7 After-Market (EST), Forecast EPS USD -0.1424

Corvus Pharma released FY2025 Q4 earnings on March 12 After-Market EST, with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.1484 (forecast USD -0.1294)

Corvus Pharma released FY2025 earnings on March 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.532 (forecast USD -0.2081)

Corvus Pharma to Release FY2025 Q4 Earnings on March 12, 2026 After-Market EST, Forecast Revenue USD 0, EPS USD -0.1294

Corvus Pharmaceuticals Postpones Release of Soquelitinib's Phase 1 Clinical Trial Results for Atopic Dermatitis

Corvus Pharma released FY2025 Q3 earnings on November 4 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1226 (forecast USD -0.1295)

Corvus Pharma released FY2025 9 Months Earnings on November 4 After-Market EST with actual revenue of USD 0 and EPS of USD -0.3576

Corvus Pharmaceuticals Reports Improved Net Loss in Q3 2025, soquelitinib Development Progresses Smoothly

Corvus Pharma to Release FY2025 Q3 Earnings on November 4 After-Market EST, Forecast Revenue USD 0, EPS USD -0.1295

Corvus Pharma released FY2025 Semi-Annual Earnings on August 7 After-Market (EST), Actual Revenue: USD 0, Actual EPS: USD -0.2606

Corvus Pharma released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1028 (forecast USD -0.1333)

Corvus Pharmaceuticals Reports Q2 Earnings

Corvus Pharma to Release FY2025 Q2 Earnings on August 7 After-Market (EST), Forecast EPS USD -0.1333

Corvus Pharmaceuticals Director Peter A. Thompson Sells 1,176,332 CRVS Shares

Angel Pharmaceuticals Gains IND Approval for Soquelitinib Clinical Trial in China

Corvus Pharmaceuticals Holds Annual General Meeting To Elect Board Members

Corvus Pharma Presents Preclinical Data on Soquelitinib

Squarepoint Significantly Boosts Holdings in Corvus

Corvus Pharmaceuticals Publishes Phase I Trial Data for Atopic Dermatitis

Amesite

InMed Pharmaceuticals

Meiwu Tech

Generation Income Properties

Co-Diagnostics

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

NextNRG

Phoenix Asia

Virax Biolabs

CRVS

SBIO

LABU

IBBQ

Oppenheimer's Jeff Jones has reiterated a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $33.00. Jones, a 5-star analyst, has an average return of 20.6% and a 43.35% success rate. Barclays also maintains a Buy rating with a $28.00 price target.

Tip Ranks

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

Oppenheimer

Whitehawk Therapeutics

Alumis

Barclays

Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer

DOCS

LWLG

ENVX

DXYZ

CSIQ

PDFS

Doximity(DOCS) fell 23%, with a trading turnover 452.3 Million USD, and a year-to-date fell 59.3%. Lightwave Logic(LWLG) fell 18.03%, with a trading turnover 256.9 Million USD, and a year-to-date rose 360.8%. Corvus Pharma(CRVS) fell 13.79%, with a trading turnover 54.8 Million USD, and a year-to-date rose 77.3%.

Top Gainers&Losers

Doximity

Lightwave Logic

Enovix

Destiny Tech100

Prestige Brands

Canadian Solar

Legence - CL

PDF Solutions

Top 10 US Stock Losers (5.14)

Corvus Pharmaceuticals presented Phase 1 data for soquelitinib, demonstrating durable drug-free remissions and a favorable safety profile. The trial involved 72 patients, showing dose-dependent efficacy with significant results in Cohorts 3 and 4. Cohort 3 achieved 50% EASI-75 and 25% IGA 0/1, while Cohort 4 reached 75% EASI-75 and 33% IGA 0/1, with no rebound effects noted. Adverse events were comparable to placebo, all Grade 1-2. Biomarker data indicated effective ITK inhibition, supporting the drug's potential.

TradingView

Proshares Ultra Nasdaq Biotech

Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety

Corvention has received FDA 510(k) clearance for its KardiaPSI™ Balloon Catheter, designed for balloon aortic valvuloplasty (BAV). This device offers an ultra high-pressure solution for the precise dilation of calcified aortic valves, enhancing predictability and accuracy in procedures. The company plans a controlled market introduction, focusing on clinical support and physician training to ensure successful implementation. The KardiaPSI™ technology aims to address challenges in valvuloplasty by providing reliable, high-performance tools for complex cases.

prnewswire

07:02 ETCorvention Announces FDA 510(k) Clearance for the KardiaPSI™ Balloon Catheter

Corvus Pharmaceuticals (NASDAQ:CRVS) stock price surpassed its 50-day moving average of $15.52, trading at $15.55 after a disappointing earnings report with an EPS of ($0.15), missing estimates by $0.01. Analysts have mixed views, with seven rating it a Buy and one a Sell. Barclays raised its target price from $16.00 to $28.00, while HC Wainwright set a new target of $27.00. Institutional investors hold 46.64% of the stock, which has a market cap of $1.31 billion and a P/E ratio of -29.90.

Market Beat

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average  After Earnings Miss

Earnings Watch

Corvus Pharma | 10-Q: FY2026 Q1 Revenue: USD 0

The clinical advancement of Soquelitinib for atopic dermatitis is progressing, with positive results from Phase 1 cohort 4. Additionally, a Phase 2 trial has been initiated during this quarter. These developments are indicative of the promising trajectory of Soquelitinib for the treatment of atopic dermatitis.

Unusual Whales

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

Corvus Pharmaceuticals (CRVS) has appointed Dr. Andrew C. Chan to its Board, emphasizing its research-driven approach. The current share price is $15.46, reflecting a 7.1% return over 30 days but a 25.3% decline over 90 days. Despite being loss-making, the stock has a year-to-date return of 111.2%. Analysts suggest a fair value of $35, indicating the stock is undervalued. Future revenue potential hinges on the success of soquelitinib and funding, with risks including clinical setbacks and capital raises.

Simplywall

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board

Corvus Pharma(CRVS.US)